Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

156 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Kinetics of emergence of liver complications in hepatitis C virus infected patients and advanced fibrosis, with and without HIV-coinfection, after sustained virological response.
Corma-Gómez A, Macías J, Téllez F, Morano L, Rivero A, Serrano M, Ríos MJ, Vera-Méndez FJ, Santos M, Real LM, Palacios R, Santos IL, Geijo P, Imaz A, Merino D, Galindo MJ, Reus-Bañuls S, López-Ruz MÁ, Galera C, Pineda JA; RIS-HEP13 and GEHEP 011 study groups. Corma-Gómez A, et al. Among authors: galindo mj. AIDS. 2021 Nov 1;35(13):2119-2127. doi: 10.1097/QAD.0000000000002959. AIDS. 2021. PMID: 34049354
Hepatitis C virus and human immunodeficiency virus coinfection in Spain.
Roca B, Suarez I, Gonzalez J, Garrido M, de la Fuente B, Teira R, Geijo P, Cosin J, Perez-Cortes S, Galindo MJ, Lozano F, Domingo P, Viciana P, Ribera E, Vergara A, Sánchez T. Roca B, et al. Among authors: galindo mj. J Infect. 2003 Aug;47(2):117-24. doi: 10.1016/s0163-4453(03)00067-7. J Infect. 2003. PMID: 12860144
Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients.
Núñez M, Mariño A, Miralles C, Berdún MA, Sola J, Hernandez-Burruezo JJ, Galindo MJ, Barreiro P, Martin-Carbonero L, Soriano V. Núñez M, et al. Among authors: galindo mj. J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):439-44. doi: 10.1097/QAI.0b013e318061b5d9. J Acquir Immune Defic Syndr. 2007. PMID: 17468669 Clinical Trial.
Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial.
Núñez M, Miralles C, Berdún MA, Losada E, Aguirrebengoa K, Ocampo A, Arazo P, Cervantes M, de Los Santos I, San Joaquín I, Echeverría S, Galindo MJ, Asensi V, Barreiro P, Sola J, Hernandez-Burruezo JJ, Guardiola JM, Romero M, García-Samaniego J, Soriano V; PRESCO Study Group. Núñez M, et al. Among authors: galindo mj. AIDS Res Hum Retroviruses. 2007 Aug;23(8):972-82. doi: 10.1089/aid.2007.0011. AIDS Res Hum Retroviruses. 2007. PMID: 17725413 Clinical Trial.
Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.
Martín-Carbonero L, Palacios R, Valencia E, Saballs P, Sirera G, Santos I, Baldobí F, Alegre M, Goyenechea A, Pedreira J, González del Castillo J, Martínez-Lacasa J, Ocampo A, Alsina M, Santos J, Podzamczer D, González-Lahoz J; Caelyx/Kaposi's Sarcoma Spanish Group. Martín-Carbonero L, et al. Clin Infect Dis. 2008 Aug 1;47(3):410-7. doi: 10.1086/589865. Clin Infect Dis. 2008. PMID: 18582203 Clinical Trial.
Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
Crespo M, Ribera E, Suárez-Lozano I, Domingo P, Pedrol E, López-Aldeguer J, Muñoz A, Viladés C, Sánchez T, Viciana P, Teira R, García-Alcalde ML, Vergara A, Lozano F, Galindo MJ, Cosin J, Roca B, Terrón A, Geijo P, Vidal F, Garrido M; VACH Cohort Study Group. Crespo M, et al. Among authors: galindo mj. J Antimicrob Chemother. 2009 Jan;63(1):189-96. doi: 10.1093/jac/dkn450. Epub 2008 Nov 6. J Antimicrob Chemother. 2009. PMID: 18988678 Clinical Trial.
Safety of Switching Nevirapine Twice Daily to Nevirapine Once Daily in Virologically Suppressed Patients.
Podzamczer D, Olmo M, Sanz J, Boix V, Negredo E, Knobel H, Domingo P, Pineda JA, Vilades C, Quero JH, Force L, Lahoz JG, Muñoz P, Llibre JM, Mariño A, Ortega E, Dalmau D, Gatell JM, Antón E, Sola J, Galindo MJ, Pedrol E, Sanz J, Lima JT, Flores J; NODy Study Group. Podzamczer D, et al. Among authors: galindo mj. J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):390-6. doi: 10.1097/QAI.0b013e318198a0cc. J Acquir Immune Defic Syndr. 2009. PMID: 19214120 Clinical Trial.
The changing face of HIV/AIDS in treated patients.
Llibre JM, Falco V, Tural C, Negredo E, Pineda JA, Muñoz J, Ortega E, Videla S, Sirera G, Martinez E, Miralles C, Iribarren J, Galindo MJ, Domingo P, d'Arminio-Monforte A, Miro JM, Clotet B. Llibre JM, et al. Among authors: galindo mj. Curr HIV Res. 2009 Jul;7(4):365-77. doi: 10.2174/157016209788680633. Curr HIV Res. 2009. PMID: 19601771 Review.
Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C.
Vispo E, Labarga P, Guardiola JM, Barreiro P, Miralles C, Rubio R, Miralles P, Aguirrebengoa K, Portu J, Morello J, Rodriguez-Novoa S, Soriano V; PERICO Study Group. Vispo E, et al. AIDS Res Hum Retroviruses. 2010 Apr;26(4):419-24. doi: 10.1089/aid.2009.0120. AIDS Res Hum Retroviruses. 2010. PMID: 20377423 Clinical Trial.
156 results